EurekaMag.com logo
+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Intramuscular pentamidine for the prevention of Pneumocystis carinii pneumonia in patients infected with human immunodeficiency virus



Intramuscular pentamidine for the prevention of Pneumocystis carinii pneumonia in patients infected with human immunodeficiency virus



Clinical Infectious Diseases 16(1): 22-25



We retrospectively reviewed the charts of 96 patients infected with human immunodeficiency virus (HIV) who received intramuscular pentamidine for the prevention of Pneumocystis carinii pneumonia (PCP). These patients, all of whom had either a history of PCP or a CD4 lymphocyte count of < or = 0.2 x 10(9)/L, were intolerant of sulfa drugs, neutropenic, or intolerant of aerosolized treatment. Intramuscular pentamidine was given monthly by the Z-track technique at a dosage of 300 mg (4 mg/kg if the patient weighed < 50 kg). During a total of 350 months of primary prophylaxis in 47 patients and 426 months of secondary prophylaxis in 49 patients, only three cases of PCP occurred. More than 73% of the patients were receiving zidovudine concomitantly. Adverse reactions to intramuscular pentamidine included two episodes of hypotension, three of sterile abscess, two of glucose intolerance, and one of asymptomatic hypoglycemia. The administration of intramuscular pentamidine by the Z-track technique for PCP prophylaxis appears to be highly effective and minimally toxic.

(PDF emailed within 0-6 h: $19.90)

Accession: 046453274

Download citation: RISBibTeXText

PMID: 8448314

DOI: 10.1093/clinids/16.1.22



Related references

Intramuscular pentamidine for the prevention of Pneumocystis carinii pneumonia in patients infected with human immunodeficiency virus. Clinical Infectious Diseases 16(1): 22-25, 1992

Prevention of pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus infected patients a clinical approach comparing aerosolized pentamidine and pyrimethamine sulfadoxine. Clinical Investigator 70(6): 508-512, 1992

Once-a-month administration of intravenous pentamidine to patients infected with human immunodeficiency virus as prophylaxis for Pneumocystis carinii pneumonia. Clinical Infectious Diseases 18(6): 901-904, 1994

Atovaquone suspension compared with aerosolized pentamidine for prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected subjects intolerant of trimethoprim or sulfonamides. Journal of Infectious Diseases 180(2): 369-376, 1999

Intrapulmonary and systemic pharmacokinetics of aerosolized pentamidine used for prophylaxis of pneumocystis carinii pneumonia in patients infected with the human immunodeficiency virus. Journal of Clinical Pharmacology 35(12): 1166-1173, 1995

Two cases of Pneumocystis carinii pneumonia occurred in human immunodeficiency virus infected patients: supplemental treatment with aerosolised pentamidine isethionate. Japanese Journal of Medicine 28(1): 105-109, 1989

Effect of aerosolized pentamidine prophylaxis on the diagnosis of Pneumocystis carinii pneumonia by induced sputum examination in patients infected with the human immunodeficiency virus. American Review of Respiratory Disease 144(4): 760-764, 1991

Treatment of Pneumocystis carinii pneumonia (PCP) with trimethoprim-sulfamethoxazole and pentamidine in human immunodeficiency virus (HIV) infected patients--a case study and review of literature. Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 62(6): 551-556, 1988

Decreased efficacy of inhaled pentamidine in the prevention of Pneumocystis carinii pneumonia among HIV-infected patients with severe immunodeficiency. Chest 103(2): 342-344, 1993

Once-weekly administration of dapsone/pyrimethamine vs. aerosolized pentamidine as combined prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clinical Infectious Diseases 20(3): 531-541, 1995

Pyrimethamine/sulfadoxine for prevention of Pneumocystis carinii pneumonia in patients infected with the human immunodeficiency virus. Clinical Infectious Diseases 19(1): 218-219, 1994

A 5-year retrospective review of adverse drug reactions and their risk factors in human immunodeficiency virus-infected patients who were receiving intravenous pentamidine therapy for Pneumocystis carinii pneumonia. Clinical Infectious Diseases 24(5): 854-859, 1997

High failure rate of dapsone and pentamidine as Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected children. Pediatric Infectious Disease Journal 13(11): 1004-1006, 1994

Antibody responses to a major pneumocystis carinii antigen in human immunodeficiency virus infected patients with and without pneumocystis carinii pneumonia. Journal of Infectious Diseases 165(6): 1151-1155, 1992

A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients. Archives of Internal Medicine 152(3): 523-528, 1992